{"authors": [["Mo", "Jia-Jie", "JJ", "Department of Functional NeurosurgeryBeijing Tiantan HospitalCapital Medical UniversityBeijing100061China."], ["Li", "Jin-Yu", "JY", "Department of General Surgerythe Second Xiangya HospitalCentral South UniversityChangsha410011China."], ["Yang", "Zheng", "Z", "Department of PsychologyGuangdong Medical UniversityZhanjiang524023China."], ["Liu", "Zhou", "Z", "Department of NeurologyAffiliated Hospital of Guangdong Medical UniversityZhanjiang524023China."], ["Feng", "Jin-Shan", "JS", "Scientific Research Center (Campus Zhanjiang)Guangdong Medical UniversityZhanjiang524023China."]], "doi": "10.1002/acn3.469", "date": "2018-01-16_23:18:17", "journal": ["Annals of clinical and translational neurology", "Ann Clin Transl Neurol"], "year": null, "title": "Efficacy and safety of anti-amyloid-\u03b2 immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis.", "id": "29296624", "text": ["review", "optimality", "safety", "different", "a\u03b2", "immunotherapies", "alzheimer", "disease", "ad", "published", "randomized", "controlled", "trials", "comprehensively", "reviewed", "electronic", "databases", "cochrane", "library", "embase", "pubmed", "google", "scholar", "pooled", "outcomes", "mean", "difference", "odds", "ratio", "values", "95", "confidence", "interval", "reported", "network", "estimates", "confidence", "predictive", "intervals", "pairwise", "relative", "effects", "evaluated", "optimal", "intervention", "ranked", "ratio", "based", "surface", "cumulative", "ranking", "curve", "eleven", "eligible", "rcts", "9", "literatures", "including", "5141", "patients", "5", "interventions", "included", "quality", "evidence", "rated", "low", "comparisons", "efficacy", "terms", "state", "examination", "aducanumab", "solanezumab", "significantly", "effective", "placebo", "safety", "terms", "imaging", "abnormalities", "aria", "bapineuzumab", "aducanumab", "significantly", "worse", "placebo", "significant", "differences", "outcomes", "alzheimer", "disease", "assessment", "subscale", "disability", "assessment", "dementia", "adverse", "events", "mortality", "given", "clinical", "therapeutic", "effects", "immunotherapies", "ad", "aducanumab", "solanezumab", "improve", "cognitive", "function", "aducanumab", "bapineuzumab", "may", "increase", "risks", "aria"]}